Don’t miss a new episode

AI Literacy First: Why Tools Without Training Backfire   

Don’t miss a new episode

1X
0:00/–:–

Handing AI tools to people who don’t know how to use them can lower performance rather than raise it. That finding reframes what an AI budget should actually buy. 

In this episode of Pharma Talks, Nataliya Andreychuk spoke with Thomas Mrosk, Founder and Managing Director at ctcHealth, and Manuel Mitola, Partner and Head of AI Consulting at ctcHealth, about AI literacy and what it takes to get value beyond the obvious tools. 

Two Ways Companies Use AI 

Thomas splits it simply: to boost productivity, or to enhance intelligence. 

His preference is starting small. Organizations are increasingly investing in the infrastructure to access large language models, often through platforms like Microsoft, which opens the door to agents that absorb routine tasks and reduce manual load. That’s where he sees the strongest near-term potential. 

Manuel’s framing is the agentic approach — AI deployed for clearly defined purposes. “This essentially means creating small, specialized AI teams to handle specific tasks. In an industry like pharma — where precision and specialization matter — this approach is especially powerful.” His read on adoption is that tools like Copilot and custom GPTs are getting noticeably better reception than they were a few months earlier. 

On the intelligence side, both point to the same strengths: analyzing large volumes of data, surfacing perspectives that weren’t visible, and taking on work people find tedious. 

Where They Push Back 

Asked whether agentic AI might end up handling most of the work — social listening, cross-channel interaction analysis — Thomas was cautious. He doesn’t subscribe to the version where AI handles nearly everything, and his reason is domain expertise. 

Rather than replacing humans, AI currently serves to augment their work. We’re guiding AI agents, not just handing over control. This has significant implications for workforce planning and the kinds of capabilities organizations need to build. 

What Makes an Agent Useful 

Manuel’s observation is that LLM output is sounding more natural, and that the value shows up in productivity and customer experience. What he finds most promising is access: “the possibility for people without technical or development backgrounds to use their domain and industry knowledge to build solutions powered by AI.” No-code platforms for building agents put capability where the subject knowledge already is. 

Thomas takes it toward the human side of adoption: 

Humanization becomes even more visible as we start interacting more regularly with AI agents. The way we handle training and change management is about to shift dramatically. These agents aren’t just useful because they’re smart. They create a safe, always available, and increasingly personalized environment for users. This opens up unprecedented support for the workforce. 

His marketing ambition is hyper-personalization — right customer, right content, real time — which he expects to become standard within about two years. 

He’s also clear about what that creates. Content production scaling by 10x or 100x makes MLR the binding constraint, which means the same tooling has to work on the compliance side. “In this context, AI won’t just accelerate marketing — it will help manage compliance too.” 

Nataliya’s qualifier: with technology moving week to week, strategic clarity is what prevents the overwhelm. A company that picks one target — accelerating clinical trial documentation, say — can see results in months rather than years. And content creation is no longer separable from MLR, since tools already handle claims, references, and compliance checks inside one workflow. 

If the Budget Doubled 

Nataliya’s question: if your marketing budget doubled tomorrow but could only be spent on AI, where would it go? 

Manuel’s answer went to literacy first, and his reasoning is the sharpest thing in the conversation. 

There’s research suggesting that if people use AI without knowing how to use it properly, their performance can actually decline. One of the biggest mistakes organizations can make is giving AI tools to employees who aren’t prepared to use them. Instead of boosting efficiency, this can have the opposite effect. 

So the money goes to training and education, because the return comes from the combination of people and tools rather than from either alone. 

Thomas would go further on the amount — triple or quadruple rather than double — while landing in the same place on sequencing. Millions spent without alignment and training won’t produce results. 

He adds change management as the piece that gets underestimated. There’s a generational dimension: some employees are more comfortable with new tools than others, and the ones who need more time need support rather than pressure. 

Closing Thought 

The pattern across both answers is that AI investment is really two investments, and the order matters. Capability without literacy produces worse outcomes than no capability at all — which is a counterintuitive enough finding that it should change how these programs get funded. 

Nataliya’s closing framing: “High-performing businesses are focused on one thing: improving outcomes and giving humanity a better chance to thrive.” 

Subscribe

To Get Pharma Talks Episodes Straight To Your Inbox.

     

    We use the details you submit to review your application and to contact you about appearing on PharmaTalks. If we go ahead, we will agree the terms of the recording with you separately, including the permissions we need to publish the episode. See the Privacy Policy for how we handle your data and the rights you have.

     

     

    FAQ

    What is Pharma Talks about?
    Pharma Talks is a pharma podcast where industry leaders discuss life sciences, commercialization, tech adoption, digital transformation, and leadership. 
    Who are Pharma Talks for?
    This pharma marketing podcast is for life sciences professionals, pharma leaders, marketers, medical teams, and innovators who want to grow and refuse to accept the industry status quo. 
    Who is the Pharma Talks host? 
    This pharmaceutical podcast is hosted by Nataliya Andreychuk, founder and CEO of Viseven, a global company that helps life sciences brands reach HCPs and patients faster with compliant and impactful content. She is also a LinkedIn voice in the industry, a member of the Forbes Agency Council, and a frequent speaker at industry events. Nataliya brings more than 20 years of experience in marketing and life sciences. 
    Can I become a guest at Pharma Talks?
    If you have experience in pharma and life sciences or have founded a brand, platform, or media, you can apply to be a guest and share your story with our audience.